85
Participants
Start Date
October 26, 2017
Primary Completion Date
November 30, 2021
Study Completion Date
December 28, 2025
Ipilimumab
YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
Nivolumab
Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
University of North Carolina at Chapel Hill, Chapel Hill
Unviersity of Wisconsin Carbone Cancer Center, Madison
University of Chicago Medical Center, Chicago
University of Utah, Huntsman Cancer Center, Salt Lake City
University of California, San Diego Moores Cancer Center, La Jolla
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Lifespan Comprehensve Cancer Center, Providence
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Toni Choueiri, MD
OTHER